Predicting early treatment discontinuation and effectiveness in bevacizumab-treated patients with advanced ovarian cancer: Exploratory analyses of the OTILIA study (on behalf of NOGGO) 7. Juli 2017 Wimberger, P., Woopen, H., Mustea, A., Oskay-Oezcelik, G., Keller, M., Harde, J., Richter, R., Wegenaer, A., Klawitter, S., Tomé, O., Sehouli, J., 2017. ESGO7–0321 (PS19) Abstract Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO. Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017. J Clin Oncol 35(suppl; abstr e12555). Weiterlesen Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – results from the prospective German TMK cohort study. Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., Marschner, N., 2017. The Breast 34, 122–130. doi:http://dx.doi.org/10.1016/j.breast.2017.05.014… Weiterlesen